2. Academic Validation
  3. Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts

Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts

  • Oncogenesis. 2019 Feb 22;8(3):15. doi: 10.1038/s41389-019-0121-7.
Chun-Hau Chen 1,  Swati Bhasin 2,  Prateek Khanna 1,  Mukta Joshi 3,  Patrick Mn Joslin 1,  Ruchi Saxena 1,  Seema Amin 1,  Suhu Liu 4,  Shreya Sindhu 2,  Sarah R Walker 4,  Paul Catalano 5,  David A Frank 4,  Seth L Alper 1,  Manoj Bhasin 6 7,  Rupal S Bhatt 8
Affiliations

Affiliations

  • 1 Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
  • 2 Department of Medicine, Division of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.
  • 3 BIDMC Genomics, Proteomics, Bioinformatics and Systems Biology Center, Beth Israel Deaconess Medical Center, Boston, MA, 02115, USA.
  • 4 Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02215, USA.
  • 5 Department of Data Sciences, Dana-Farber Cancer Institute, Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • 6 Department of Medicine, Division of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA. [email protected].
  • 7 BIDMC Genomics, Proteomics, Bioinformatics and Systems Biology Center, Beth Israel Deaconess Medical Center, Boston, MA, 02115, USA. [email protected].
  • 8 Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. [email protected].
PMID: 30796200 DOI: 10.1038/s41389-019-0121-7
Abstract

Several therapeutic options are available for metastatic RCC, but responses are almost never complete, and resistance to therapy develops in the vast majority of patients. Consequently, novel treatments are needed to combat resistance to current therapies and to improve patient outcomes. We have applied integrated transcriptome and proteome analyses to identify Cathepsin B (CTSB), a cysteine proteinase of the papain family, as one of the most highly upregulated gene products in established human RCC xenograft models of resistance to vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI). We used established RCC models to test the significance of CTSB in the progression of renal Cancer. Our evaluation of CTSB showed that stable CTSB knockdown suppressed RCC growth in vitro and in vivo. Stable over-overexpression of wild-type CTSB (CTSBwt/hi), but not of an CTSB active site mutant (CTSBN298A), rescued cell growth in CTSB knockdown cells and abolished the efficacy of VEGFR TKI treatment. Genome-wide transcriptome profiling of CTSB knockdown cells demonstrated significant effects on multiple metabolic and stem cell-related pathways, with ALDHA1A (ALDH1) as one of the most significantly downregulated genes. Importantly, survival analysis across 16 major TCGA cancers revealed that CTSB overexpression is associated with low rates of three and five year patient survival rates (P = 2.5e-08, HR = 1.4). These data strongly support a contribution of CTSB activity to RCC cell growth and tumorigenicity. They further highlight the promise of CTSB inhibition in development of novel combination therapies designed to improve efficacy of current TKI treatments of metastatic RCC.

Figures
Products